RecruitingPhase 2NCT07486869

Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study

Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease

Sponsor

University of Miami

Enrollment

5 participants

Start Date

Jul 23, 2026

Study Type

INTERVENTIONAL

Conditions

Interstitial Lung Disease Dermatomyositis Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)Dermatomyositis Sine Myositis Dermatomyositis With Myopathy Dermatomyositis With Respiratory Involvement Dermatomyositis With Organ Involvement

Summary

This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Emapalumab for people with dermatomyositis, dermatomyositis sine myositis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEmapalumab

Emapalumab administered intravenously according to the following dosing regimen: 6 mg/kg on Day 1, followed by 3 mg/kg every 3 days for 2 weeks, and then 3 mg/kg twice weekly for 2 weeks.